CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. "In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease
<i>-HCV: Rolling submission of New Drug Application for telaprevir
expected to begin in summer of 2010; first Phase 3 SVR data expected in
second quarter 2010 from ADVANCE trial-</i>
<br />
<i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of
Phase 3 registration program for VX-770; data expected in first half of
2011-</i>
<br />
<i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical
trials with compounds for rheumatoid arthritis and epilepsy and with
novel combination regimens for HCV and CF-</i>
<br />
<i>-Financial: Vertex ends first quarter with cash position of
approximately $1.1 billion-</i>
<br />
Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.
Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.
- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -
Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was
- VX-950 Global Phase 2b Clinical Development Plan On Track -<br>
- Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company,
Adds Important Strengths<br>
and Development Capabilities for VX-950 -